Home>
Stocks>
Sakar Healthcare Ltd

Sakar Healthcare Ltd (SAKAR)

₹345.6▲0.17%

Get free price alerts. Set up your Free investment account to get Live Prices. >

Overview

Fundamentals

Q3 '23 Results

Technicals

News and Events

Sakar Healthcare Ltd share Performance

₹343.95
₹351.9
₹345.6
0.48%
Low
Day's Volatility:2.30%
High
1.82%
₹230.05
₹479
₹345.6
33.43%
Low
52 Weeks Volatility:72.03%
High
38.60%

Returns %
1 Month Return	-4.49 %
3 Month Return	-14.12 %
1 Year Return	+ 45.66 %

Market Stats
Previous Close	₹₹345.00
Open	₹₹351.90
Volume	₹6,038.00
Upper Circuit	₹-
Lower Circuit	₹-
Market Cap	₹₹750.37Cr

Company Information

Sakar Healthcare Limited, formerly Sakar Healthcare Private Limited, was incorporated in March 2004. The company is promoted by Sanjay Shah, Rita Shah and Aarsh Shah and is in the business of contract manufacturing of pharmaceutical products for Indian companies as well as manufacturing and marketing its own formulations for domestic and international markets. Its products range from analgesics and anti coagulants to antianemics, antibiotics, antiemetics, antihistamines, bronchodilators, corticosteroids, cough and cold preparations and multivitamins. Sakar Healthcare prides itself in its high quality and reliable products, time-bound delivery and personalized after-sales-service.

Share Price: ₹345.60 per share as on 17 May, 2024 04:01 PM
Market Capitalisation: ₹750.37Cr as of today
Revenue: ₹37.23Cr as on December 2023 (Q4 23)
Net Profit: ₹2.07Cr as on December 2023 (Q4 23)
Listing date: 14 Oct, 2016
Chairperson Name: Sanjay S Shah.

Organisation	Sakar Healthcare Ltd
Headquarters	Ahmedabad
Industry	Pharmaceuticals
E-voting on shares	Click here to vote

Key events for Sakar Healthcare Ltd

Sakar Healthcare Oncology Unit Attains EU GMP Approval - 06 Mar, 2024
Sakar Healthcare's oncology unit has received EU GMP approval, opening doors for significant export opportunities and strengthening its position in the global oncology market.

Fundamentals of Sakar Healthcare Ltd

Insights on Sakar Healthcare Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 34.74 Cr → 37.46 Cr (in ₹), with an average increase of 7.3% per quarter
POSITIVE IMPACT
Retail Holding Up
Retail Investor have increased holdings from 22.47% to 22.71% in Mar 2024 quarter
POSITIVE IMPACT
Best in 3 Years
In the last 3 years, SAKAR has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
NO EFFECT
Against Peers
In the last 1 year, Zydus Lifesciences Ltd has given 94.5% return, outperforming this stock by 48.8%
NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 53.15% of holdings in Mar 2024 quarter
NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, 3.64 Cr → 2.07 Cr (in ₹), with an average decrease of 43.1% per quarter
NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 13.76% to 13.52% in Mar 2024 quarter
NEGATIVE IMPACT
Price Dip
In the last 6 months, SAKAR stock has moved down by -10.4%